| Prophylactic ampicillin use |
Ampicillin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is blaTEM gene |
Swine |
Grower-finisher |
1 |
| Therapeutic tiamulin use |
Tiamulin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic amikacin use |
Amikacin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic chloramphenicol use |
Chloramphenicol use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic imipenem use |
Imipenem use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therpeutic AMU |
Resistance outcome is blaTEM gene |
Swine |
Grower-finisher |
1 |
| Prophylactic tobramycin use |
Tobramycin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is catA gene |
Swine |
Grower-finisher |
1 |
| Therpeutic AMU |
Resistance outcome is blaCTX-M9 gene |
Swine |
Grower-finisher |
1 |
| Therapeutic piperacillin use |
Piperacillin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic marbofloxacin use |
Marbofloxacin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is sul3 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic cefpodoxime use |
Cefpodoxime use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is dfrA12 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is aadA2 gene |
Swine |
Grower-finisher |
1 |
| Therapeutic ampicillin use |
Ampicillin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is dfrA12 gene |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is aadB gene |
Swine |
Grower-finisher |
1 |
| Therapeutic tetracycline use |
Tetracylcine use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic tetracycline use |
Tetracylcine use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic cefpodoxime use |
Cefpodoxime use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic amoxicillin use |
Amoxicillin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is sul1 gene |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is aadA1 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is dfrA10 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic tiamulin use |
Tiamulin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is aadA2 gene |
Swine |
Grower-finisher |
1 |
| Therapeutic ceftiofur use |
Ceftiofur use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is tetB gene |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is Int1 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic nitrofurantoin use |
Nitrofurantoin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic gentamicin use |
Gentamicin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic cefpirome use |
Cefpirome use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is sul1 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic gentamicin use |
Gentamicin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic Amoxicillin/clavulanic acid use |
Amoxicillin/clavulanic acid use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is sul2 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic cefpirome use |
Cefpirome use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is aadA1 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is sul3 gene |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is cmlA gene |
Swine |
Grower-finisher |
1 |
| Prophylactic ceftiofur use |
Ceftiofur use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic Amoxicillin/clavulanic acid use |
Amoxicillin/clavulanic acid use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is tetA gene |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is aadB gene |
Swine |
Grower-finisher |
1 |
| Therapeutic enrofloxacin use |
Enrofloxacin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic cefalexin use |
Cefalexin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is dfrA1 gene |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is dfrA1 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic piperacillin use |
Piperacillin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic amoxicillin use |
Amoxicillin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic amikacin use |
Amikacin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is blaCTX-M-1 gene |
Swine |
Grower-finisher |
1 |
| Therapeutic imipenem use |
Imipenem use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is catB gene |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is dfrA10 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is cmlA gene |
Swine |
Grower-finisher |
1 |
| Prophylactic Trimethoprim/sulfamethoxazole use |
Trimethoprim/sulfamethoxazole use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic tobramycin use |
Tobramycin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is blaCTX-M9 gene |
Swine |
Grower-finisher |
1 |
| Therapeutic cefalexin use |
Cefalexin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic nitrofurantoin use |
Nitrofurantoin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is tetB gene |
Swine |
Grower-finisher |
1 |
| Prophylactic enrofloxacin use |
Enrofloxacin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is tetA gene |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is ESBP E. coli gene |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is Int1 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is ESBP E. coli gene |
Swine |
Grower-finisher |
1 |
| Prophylactic AMU |
Resistance outcome is catB gene |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is blaCTX-M-1 gene |
Swine |
Grower-finisher |
1 |
| Prophylactic chloramphenicol use |
Chloramphenicol use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic Trimethoprim/sulfamethoxazole use |
Trimethoprim/sulfamethoxazole use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is sul2 gene |
Swine |
Grower-finisher |
1 |
| Therapeutic marbofloxacin use |
Marbofloxacin use broken up by treatment group |
Swine |
Grower-finisher |
1 |
| Therapeutic AMU |
Resistance outcome is catA gene |
Swine |
Grower-finisher |
1 |